| Document |
Document Title |
|
JP2007532550A |
Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen defic...
|
|
JP2007522087A |
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a...
|
|
JP2007521293A |
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a...
|
|
JP2007521297A |
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficie...
|
|
JP2007521292A |
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficie...
|
|
JP2007517788A |
The invention relates to a method for producing 1,2-unsaturated azasteroids of general formula (I), from a structurally related, saturated azasteroid of general formula (II).
|
|
JP2007517025A |
The present invention relates to a composition for preventing and treating metabolic syndrome, containing tanshinone derivatives as an effective ingredient. More specifically, the present invention relates to a composition for preventing...
|
|
JP3927174B2 |
17-methylene-4-azasteroid compounds of formula I: wherein R20 denotes fluoro, chloro or bromo R20a denotes hydrogen, R10 and R4 each denote a hydrogen atom or a methyl group, and R1 and R2 each denote a hydrogen atom or together denote a...
|
|
JP2007509962A |
Compounds of structural formula (I) are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of...
|
|
JP2007507219A |
The present invention relates to a microbial method for the simultaneous dehydrogenation and oxidation of 4-an-drosten-3,17-dione to produce 17a-oxo-D-homo-1,4-andrustadiene-3,17-dione in high yield and high substrate concentrations, by ...
|
|
JP2007063296A |
To provide a medicinal composition useful for treating human prostatic adenocarcinoma.The medicinal composition for treating human prostatic adenocarcinoma comprises a 5-α-reductase inhibiting compound of 17β-(N-t-butylcarboxamide)-5-Î...
|
|
JP2007505120A |
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. These compounds are useful in the enhancement of weakened muscle tone and the treatment of conditions caused by androgen deficie...
|
|
JP2007505118A |
Compounds of structural formula I are modulators of the androgen receptor (AR) in a tissue selective manner. They are useful as agonists of the androgen receptor in bone and/or muscle tissue while antagonizing the AR in the prostate of a...
|
|
JP2006290822A |
To provide a method for extracting miroesterol which is one of an estrogen like acting substance, from a lumpy root part of a leguminous plant by a simple and short operation in a good efficiency.This method for producing a miroesterol c...
|
|
JP3820349B2 |
A sulphamate compound suitable for use as an inhibitor of oestrone sulphatese (E.C.3.1.6.2) is described. The compound is a polycyclic compound comprising at least two ring components, wherein the polycyclic compound comprises at least o...
|
|
JP2006506445A |
The invention relates to the use of compounds to ameliorate or treat an condition such as a cystic fibrosis, neutropenia or other exemplified conditions. Exemplary compounds that can be used include 3²-hydroxy-17²-aminoandrost-5-ene, 3...
|
|
JP2006503831A |
The present invention provides water soluble triptolide derivatives of formula I, II, IIIa, and IIIb, which have high immunosuppressive activity and in which R1 and R2 have the same meanings as defined in claims. The present invention al...
|
|
JP2005538061A |
This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions related to elevated intraocular pressure in the eye of a patient. This invention also relat...
|
|
JP2005533055A |
This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions related to elevated intraocular pressure in the eye of a patient. This invention also relat...
|
|
JP2005504130A |
A 4-stage process is claimed for the preparation of 17beta -substituted 3-oxo-delta 1>,2-4-aza-steroids (I) from the 1,2-saturated analogs (II), via new fused hydroxy-oxazolidinedione aza-steroid derivative intermediates (IV) and new 2-s...
|
|
JP2004538307A |
Compounds of structural formula (I) as herein defined are disclosed as useful in a method for modulating the androgen receptor in a tissue selective manner in a patient in need of such modulation, as well as in a method of agonizing the ...
|
|
JP2004534796A |
A process for the preparation of compounds of formula (I) in which R1, R2, R3 and n are defined as indicated in the description, use of said compounds as intermediates for the preparation of estrogen derivatives as well as the intermedia...
|
|
JP2004508380A |
The present invention relates to a novel polymorphic form of 17- beta -(N-ter.butyl carbamoyl)-4-aza-5-- alpha -androst-1-en-3-one (Finasteride) of the formula (I) and processes for preparing the form.
|
|
JP2003513103A |
Polymorphic Form (I) finasteride is prepared by first forming a substantially insoluble complex of finasteride and a Group (I) or Group (II) metal salt, such as lithium bromide, and then dissociating the complex by dissolving away the sa...
|
|
JP2003512474A |
The present invention provides methods and compositions to prevent or treat a hematopoietic disorder such as thrombocytopenia or neutropenia by administering to a subject an effective amount of a steroid such as 3,7,16,17-tetrahydroxy-an...
|
|
JP2003503507A |
17 beta -(N-tert-butylcarbamoyl)-3-one-4-aza-steroids (I) can be obtained by a process which comprises the reaction of 17( beta -(alkoxycarbonyl)-3-one-4-aza-steroid with lithium tert-butylamide in an organic solvent. Some compounds of f...
|
|
JP2002540119A |
The invention provides compositions comprising formula 1 steroids, e.g., 16alpha-bromo-3beta-hydroxy-5alpha-androstan-17-one hemihydrate and one or more excipients, typically wherein the composition comprises less than about 3% water. Th...
|
|
JP2002539166A |
The topical application, at a dose rate less than or equal to 0.1 mg day, to the ocular surface or adjacent regions of the eye of a preparation containing a therapeutically effective amount of an androgen or androgen analogue or a therap...
|
|
JP2002539166A5 |
|
|
JP2002308776A |
To provide a medicinal composition useful in the therapy for human prostatic adenocarcinoma.The medical composition for treating human prostatic adenocarcinoma contains a 5-α-reductase inhibiting compound such as 17β-(N-t- butylcarboxy...
|
|
JP3337689B2 |
Compounds of the formula or a pharmaceutically acceptable salt or ester thereof, wherein R1 is selected from the group consisting of hydrogen and C1-10 alkyl; R2 is selected from the group consisting of hydrogen and C1-10 alkyl; R3 is se...
|
|
JP2002534955A |
The present invention is directed to certain novel compounds represented by structural formula (I) or a pharmaceutically acceptable salt thereof, wherein R<3>, R<6>, R<7>, R<8>, R<11>, R<12>, R<13>, A, Q, W, X, Y, Z and n are defined her...
|
|
JP3325026B2 |
PCT No. PCT/US94/07220 Sec. 371 Date Oct. 31, 1995 Sec. 102(e) Date Oct. 31, 1995 PCT Filed Jun. 27, 1994 PCT Pub. No. WO95/00147 PCT Pub. Date Jan. 5, 1995Compounds of formula (I), wherein: R1 is selected from the group consisting of hy...
|
|
JP3325025B2 |
Compounds of formula (I) (I) wherein: the symbol represents a single or a double bond; B is a bond or a straight or branched C1-C6 alkylene chain; R is hydrogen or C1-C4 alkyl; R1 is hydrogen, C1-C6 alkyl or benzyl; R2 is a) hydrogen, fl...
|
|
JP3300359B2 |
PCT No. PCT/HU93/00040 Sec. 371 Date Dec. 6, 1995 Sec. 102(e) Date Dec. 6, 1995 PCT Filed Jun. 24, 1993 PCT Pub. No. WO95/00532 PCT Pub. Date Jan. 5, 1995The invention relates to novel 4-azaandrostene intermediates of formula (I), (I) wh...
|
|
JP3293629B2 |
A 7-substituted oxa- or azasteroid compound represented by general formula (I), which has an excellent aromatase-inhibiting effect and is useful for preventing or treating diseases caused by estrogens, such as breast cancer, uterine canc...
|
|
JP3293623B2 |
A compound represented by general formula (I), which has an aromatase inhibitory activity and is useful for preventing and treating diseases caused by hyperestrogenosis, such as mastocarcinoma, metrocarcinoma and prostatomegaly. In formu...
|
|
JP2002512209A |
The invention relates to a method for carrying out photochemical and thermochemical solar syntheses by means of flat-bed solar light collectors without devices for focusing the sunlight. The method is particularly well suited for produci...
|
|
JP3253088B2 |
The invention relates to a novel process for preparing 17 beta -substituted 4-azaandrostane derivatives of general formula (I) wherein R represents hydrogen or a C1-3alkyl group; R<1> represents a carboxamido group mono- or disubstituted...
|
|
JP2001523259A |
4-Aza-steroid compounds are provided, which have functional groups at one or more of positions 7, 11 and 15, such as hydroxyl or hydroxyl derivative groups. The compounds are active against 5-alpha-reductase giving indications of utility...
|
|
JP2001523219A |
Process for preparing steroids having a carboxamide side-chain of formula (I) wherein: the formula - - - are each independently, single or double bonds; z is a single bond, or a straight or branched C1-C5 alkylene; the moiety represents ...
|
|
JP2001521000A |
This invention is concerned with the prevention of precipitated acute urinary retention in a subject male susceptible thereto by the administration of an inhibitor of 5 alpha -reductase to the subject. The present invention also provides...
|
|
JP2001515518A |
PCT No. PCT/EP98/08527 Sec. 371 Date Aug. 27, 1999 Sec. 102(e) Date Aug. 27, 1999 PCT Filed Dec. 17, 1998 PCT Pub. No. WO99/35161 PCT Pub. Date Jul. 15, 1999A process for producing a compound of formula (I): wherein the dotted lines - - ...
|
|
JP2001514666A |
Disclosed is a method of preparing a compound represented by the following structural formula: The method comprises reacting bromine (Br2) and an aliphatic organic acid with a compound represented by the following structural formula: R1 ...
|
|
JP3202229B2 |
PCT No. PCT/EP91/02239 Sec. 371 Date Sep. 28, 1993 Sec. 102(e) Date Sep. 28, 1993 PCT Filed Nov. 27, 1991 PCT Pub. No. WO92/09618 PCT Pub. Date Jun. 11, 1992.8-En-19,11 beta -bridged steroids of general formula I (I) that have the 8,9-do...
|
|
JP3182072B2 |
To obtain cotton fibers improved in fiber properties such as increased fiber length, fineness and higher fiber strength by treating a cotton plant belonging to the genus Gossypium with a brassinosteromd and collecting cotton fibers there...
|
|
JP3164389B2 |
PURPOSE: To obtain a 4-azasteroid useful as a therapeutic agent for prostatic hypertrophy, having excellently inhibitory action on testosterone-5α-reductase. CONSTITUTION: A compound of formula I [R1 is H or (substituted) 1-6C alkyl wit...
|
|
JP3141053B2 |
PURPOSE: To obtain the new subject compound useful as a therapeutic agent for bone diseases such as osteoporosis, rheumatoid arthritis and osteoarthritis because of exhibition of hormone action as estrogen. CONSTITUTION: A compound of fo...
|
|
JP2000309536A |
To obtain the subject composition useful for treating prostatic adenocarcinoma by including a specific steroid 5-α-reductase inhibiting compound and a carrier. This pharmaceutical composition is obtained by including (A) a steroid 5-α-...
|
|
JP2000505444A |
The invention related to 4-aza-17 beta -(cyclopropoxy)-androst-5 alpha -androstan-3-one, 4-aza-17 beta -(cyclopropylamino)-androst-4-en-3-one and related compounds and to compositions incorporating these compounds, as well as the inhibit...
|
